Can pharma tariffs “Make America Manufacture Again”?
Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.

Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.
Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Next-generation targeting for evolving HCP engagement
Are regulators keeping pace with AI adoption in clinical trials?
Recursion axes drug programmes to streamline pipeline
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos